相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Aileen Fernandez et al.
JAMA ONCOLOGY (2022)
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer-Should We Go All In?-Reply
Paolo Tarantino et al.
JAMA ONCOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
Akitaka Makiyama et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
Federica Grillo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
Eric Van Cutsem et al.
GASTRIC CANCER (2015)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
Fei Zhou et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2012)
Impact of HER-2 Overexpression/Amplification on the Prognosis of Gastric Cancer Patients Undergoing Resection: A Single-Center Study of 1,036 Patients
Jun-Te Hsu et al.
ONCOLOGIST (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
J. D. Barros-Silva et al.
BRITISH JOURNAL OF CANCER (2009)
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
C. Gravalos et al.
ANNALS OF ONCOLOGY (2008)
Assessment of a HER2 scoring system for gastric cancer:: results from a validation study
M. Hofmann et al.
HISTOPATHOLOGY (2008)
HER-2/neu amplification is an independent prognostic factor in gastric cancer
Dong Il Park et al.
DIGESTIVE DISEASES AND SCIENCES (2006)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:: an immunohistochemical and fluorescent in situ hybridization study
A Ooi et al.
MODERN PATHOLOGY (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
HER-2 expression and cell proliferation:: Prognostic markers in patients with node-negative breast cancer
A Volpi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas
FR Hirsch et al.
BRITISH JOURNAL OF CANCER (2002)
Her-2/neu and breast cancer
S Kaptain et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2001)